Introduction
Ameriprise Financial Inc. has significantly increased its stake in Applied Materials, Inc. (NASDAQ: AMAT), purchasing 3,583,751 additional shares in the third quarter. This move, which raised its ownership to 12,520,114 shares, highlights growing institutional confidence in the semiconductor equipment giant. With AMAT now representing 0.6% of Ameriprise’s portfolio, the stock ranks as its 19th largest holding. Let’s explore the implications of this investment and recent developments shaping AMAT’s trajectory.
Why Institutional Investors Are Buying AMAT
Ameriprise’s Strategic Move
Ameriprise’s 40.1% stake increase in AMAT reflects a calculated bet on the semiconductor industry’s resilience. The firm now owns 1.57% of AMAT’s shares, valued at $2.56 billion. This aligns with broader institutional trends: Marquette Asset Management and Redmont Wealth Advisors also boosted their holdings, while new entrants like Financial Gravity Companies and Howard Hughes Medical Institute added positions in Q2 and Q3 2026.
Market Catalysts Driving AMAT
- Dividend Growth: AMAT raised its quarterly dividend by 15% to $0.53, signaling strong free cash flow and long-term stability.
- S&P 100 Inclusion: The stock’s upcoming addition to the S&P 100 index is expected to attract index-tracking funds.
- AI & Memory R&D: Partnerships with SK hynix and Micron on next-gen DRAM/HBM memory tech are boosting equipment demand.
- Institutional Overweight: Hedge funds and money managers are favoring semiconductor equipment stocks, including AMAT, as AI spending dominates 2026.
AMAT’s Recent Performance and Risks
Stock Price and Financials
AMAT shares opened at $341.53 on March 15, 2026, up 1.3% from previous levels. The stock’s 52-week range is $123.74 to $395.95, with a 50-day moving average of $334.48. Despite a 2.1% quarterly revenue decline, AMAT reported $2.38 EPS, exceeding estimates. Analysts project 2026 EPS of $9.38, with a current P/E ratio of 34.96 and a PEG ratio of 1.54.
Analyst Sentiment and Price Targets
Goldman Sachs, Needham, and Barclays have raised AMAT’s price targets to $390–$450, citing AI-driven demand. The stock carries a “Moderate Buy” consensus rating, with a median price target of $363.46. However, risks persist: macroeconomic factors like energy prices and geopolitical tensions could pressure tech cyclicals.
Insider Activity and Market Position
Recent insider activity includes CAO Adam Sanders selling 534 shares for $202,471.44, reducing his holdings by 10.35%. Meanwhile, institutional ownership stands at 80.56%, with major players like Manning & Napier Advisors and Howard Hughes Medical Institute entering the fray. AMAT’s market cap of $271 billion reflects its dominance in semiconductor equipment, though elevated beta (1.65) signals higher volatility.
Conclusion: Is AMAT a Buy?
Ameriprise’s stake increase, coupled with AMAT’s dividend growth and AI-focused partnerships, paints a bullish picture. However, investors should monitor macro risks and insider selling trends. For those seeking long-term exposure to the semiconductor sector, AMAT remains a compelling choice—provided they balance optimism with caution. Check out our latest stock analysis for real-time updates on AMAT’s performance.
